News & Updates

In individuals with immune-mediated inflammatory diseases (IMIDs*), a 2-week interruption in methotrexate (MTX) treatment led to enhanced COVID-19 booster vaccine response compared with those who continued with MTX treatment, according to findings from the VROOM** study.

People living with HIV (PLWH) are less likely to receive preventive cardiovascular (CV) care than non-HIV-infected patients, suggest the results of a study conducted in the same outpatient clinic.

A large global study of patients with severe COVID-19 admitted to the intensive care unit (ICU) has shown a 14 percent prevalence of haemorrhagic, coagulopathic, and thrombotic (HECTOR) complications in these patients, with mortality risk increased in those with haemorrhagic complications. 

People living with HIV (PLWH) are less likely to receive appropriate statin therapy for the prevention of atherosclerotic cardiovascular disease (ASCVD), a study has found.

Hospitalized patients with COVID-19 who are receiving remdesivir and other standard care show no improvements in clinical outcomes with the addition of ensovibep, according to the results of a study.

Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.